Vor Biopharma Inc. - 8-K Filing
Vor Biopharma Inc. filed an 8-K on June 8, 2026, announcing that RemeGen Co., Ltd. received conditional approval from China's NMPA for telitacicept in treating IgA nephropathy and full approval for Sjögren’s disease. The approvals are based on positive Phase 3 trial results showing a 59% reduction in urinary protein-to-creatinine ratio at Week 39 for IgAN patients, as well as statistically significant improvements in ESSDAI scores for SjD patients. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $VOR